The expression of Na + -K + -2cl − cotransporter 1 (NKcc1) is upregulated in spontaneously hypertensive rat (SHr). We investigated whether expression of NKcc1 is epigenetically regulated during postnatal development of hypertension.
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The Na + -K + -2Cl − cotransporter 1 (NKCC1) belongs to the solute carrier family 12 and provides electroneutral symport of sodium, potassium, and chloride. 1 NKCC1 is expressed in most of the cells including vascular smooth muscle cells, endothelial cells, cardiomyocytes, neurons, glial cells, and blood cells whereas NKCC2, a kidney-specific isoform, is exclusively expressed in the apical membranes of thick ascending limb and macula densa and plays a major role in renal hand ling of salt. 1 NKCC1 is involved in contraction of vascular smooth muscle cells dependent on cell volume. 2 The evidence that NKCC1 is implicated in the maintenance of vascular tone in vivo is reported in experiments with Nkcc1 −/− mice. The systolic blood pressure is attenuated by 15-20 mm Hg without any changes of heart function in Nkcc1 −/− mice. 3 Intravenous infusion of bumetanide, a specific NKCC inhibitor, causes a rapid reduction of mean arterial blood pressure and vascular tone in resistance arteries, which is abolished in Nkcc1 −/− mice. 4 Bumetanide also inhibited contractions and myogenic tone in mesenteric arteries isolated from wild-type mice, but not from Nkcc1 − mice. 5 Hypertension induced by deoxycorticosterone/salt, 6 angiotensin II, 7 and aortic coarctation 4, 8 shows the increased level of Nkcc1 mRNA and activity, whereas aldosterone increases only NKCC1 activity without inducing Nkcc1 mRNA expression. 9 Also, several research groups proposed that augmented ion fluxes mediated by NKCC1 detected in erythrocyte and vascular smooth muscle cells from spontaneously hypertensive rat (SHR) and Milan hypertensive strain contribute to the pathogenesis of hypertension. 10, 11 It is well known that NKCC1 activity is regulated by diverse signaling pathways including recently discovered with no lysine kinase family. 12 Recently, we reported that Nkcc1 promoter is hypometh ylated in aorta and heart of established hypertensive rat. 13 Nevertheless, 1 department of Pharmacology, Kyungpook National University School of medicine, daegu, republic of Korea; 2 cmrI, Kyungpook National University School of medicine, daegu, republic of Korea; 3 it is not known whether differential status of methylation between Wistar-Kyoto (WKY) and SHR is inherited or not. The epigenetic regulation of NKCC1 expression during postnatal development of hypertension is not clear. In the present study, we tested the hypothesis that expression of NKCC1 is epigenetically regulated during postnatal development of hypertension.
methodS

Animals.
The investigation was in accordance with Guide for the Care and Use of Laboratory Animals in Kyungpook National University School of Medicine. All efforts were made to minimize both the number of animal used and their suffering. Male 5, 10, and 18 week-old WKY/Izm and SHR/ Izm were purchased from SLC (Shizuoka, Japan). In this study, 5-, 10-, and 18-week-old SHR were regarded as early, mild, and established hypertension, respectively. Under anesthesia with sodium pentobarbital, the organs of heart, kidneys, and aortas were excised and kept at −80 °C until further analysis.
Blood pressure measurement in WKY and SHR. Systolic blood pressures were checked by the tail-cuff method using the NIBP controller system (ADInstruments, Castle Hill, Australia).
Preparation of mesenteric arteries and tension recording.
The mesentery bed was removed and the first order branches of mesenteric arteries from 5-week-old rats and the third order branches of mesenteric arteries from 10-and 18-week-old rats were used for experiment. Experiments were performed as previously described. 14 Protein extraction and western blot. The frozen tissues were homogenized in radio-immunoprecipitation assay buffer containing protease inhibitors. Western blot analysis were performed as previously described. 13 The expression levels were quantified by optical densitometry using ImageJ software.
Quantitative real-time RT-PCR. RNA was extracted using Trizol Reagent (Invitrogen, Carlsbad, CA) according to manufacturer's recommendations. Total RNA (2 μg) was reverse-transcribed into cDNA using RevertAid first strand cDNA synthesis (Fermentas EU, Glen Burnie, MD). Real-time PCR was performed using SYBR Green PCR master mix (TaKaRa, Japan) and ABI Prism 7000 sequence detection system (Applied Biosystems, Foster City, CA). The relative mRNA expression level was determined by calculating the values of Δ cycle threshold (ΔC t ) by normalizing the average C t value compared with its endogenous control (Gapdh) and then calculating 2 −ΔΔCt . 15 All primer sets used in real-time PCR were shown in Supplementary Table S1 online.
DNA bisulfite modification and sequencing. The isolated DNA was modified by sodium bisulfite as described previously with a minor modification. 16 After bisulfite modification, PCR on the CpG island (−370 to −138) of the Nkcc1 was performed, and PCR products were inserted into T-easy vector (Promega, Madison, WI). Five independent clones containing the exactsized insert for each amplified fragment were sequenced. Primer set used in bisulfate modified PCR was shown in Supplementary Table S1 online.
DNA methyltransferase (DNMT) activity. DNMT activity was measured using EpiQuik DNA Methyltransferase Activity/ Inhibition Assay Kit (Epigentek, Brooklyn, NY), using nuclear extracts from aorta. Nuclear extracts were isolated using the EpiQuik Nuclear Extraction Kit (Epigentek) and 3 μl of nuclear extract was added to each reaction well, according to manufacturer's protocol. Results are given in activity units expressed compared to the activity level detected in 5-weekold WKY.
Chromatin immunoprecipitation (ChIP) assay. ChIP analysis was performed according to the manufacturer's protocols with some modification using EZ ChIP (Upstate Biotechnology, Lake Placid, NY). Antibodies to acetyl-histone H3, dimethyl-H3-K4, and dimethyl-H3K9 were obtained from Upstate Biotechnology. Antibodies to DNMT3B and methyl-CpG-binding protein 2 (MeCP2) were obtained from Abcam (Cambridge, UK). Antibody to CXXC finger protein 1 (Cfp1) was obtained from Santa Cruz. DNA fragments were amplified by PCR. Primer set used in PCR was shown in Supplementary Table S1 online.
Statistical analysis. Data are expressed as mean ± s.e.m. and were analyzed by repeated measures analysis of variance followed by post hoc Duncan test for tension measurement or one-way analysis of variance followed by post hoc Duncan test for comparing expression level of NKCC1 or other genes. A P value <0.05 was considered to be statistically significant. Table 1 shows the EC 50 and E max in mesenteric artery from 5-, 10-, and 18-week-old WKY and SHR. nkcc1 expression in aorta, heart, and kidney from wky and Shr
In order to confirm whether the NKCC1 protein is different between WKY and SHR during increased blood pressure, we performed western blot using aorta, heart, and kidney tissues from 5-, 10-, and 18-week-old WKY and SHR. In WKY, NKCC1 protein was increased in aorta with age (Figure 2a) , but was maintained in heart and kidney of all ages (Figure 2b,c) .
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The protein level of NKCC1 showed gradual increase in aorta, heart, and kidney of SHR with age (Figure 2a-c) . At the age of 18 weeks, the protein levels in SHR were about twofold higher than those in WKY, though the protein levels were different among tissues.
Nkcc1 mRNA was significantly decreased in WKY aorta and heart (Figure 2d ,e) or constant in that of kidney with age ( Figure 2f) . While, as SHR got older, mRNA level was increased in aorta and kidney (Figure 2d,f) . Although Nkcc1 expression level of heart in SHR was maintained with age ( Figure 2e ), Nkcc1 mRNA levels at 18-week-old heart tissues from SHR were higher than those of WKY.
comparison of dna methylation status of Nkcc1 promoter in wky and Shr
In order to investigate the status of Nkcc1 promoter methylation, we determined the methylation level by using bisulfite sequencing in promoter from WKY and SHR aorta. Bisulfite sequencing revealed that Nkcc1 promoter from aorta of SHR was significantly hypomethylated with age (2.2%, n = 5) (Figure 3b right and 3c ) compared with those of WKY which was methylated in aorta (8.5%, n = 5) (Figure 3b left and 3c) . The DNMT activity showed no difference between WKY and SHR at 5-10 weeks of age. At the age of 18 weeks, WKY had 2.7-fold higher DNMT activity than SHR. DNMT3B, which is participated in de novo DNA methylation, and MeCP2, which is a kind of methylated DNA-binding proteins, enriched in WKY with age (Figure 3e-g ). These changes were marker of inactivation of the Nkcc1 gene and were correlated with the hypermethylation on the Nkcc1 promoter region in WKY (Figure 3b-d) . Cfp1, which specifically binds to unmethylated cytosine of CpG island, was shown to highly associate with the promoters of SHR but least with that of 18-week-old WKY which was methylated (8.5%) (Figure 3h) .
changes of histone modification in wky and Shr
To determine whether there were covalent modification on histone in the Nkcc1 promoter region during blood pressure original contributions
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increase, we did ChIP analysis with various antibodies. SHR showed enrichment of acetylated histone H3 and H3 dimethylated at lysine 4 on the Nkcc1 promoter region with age (Figure 4a-c) . In addition, results showed that dimethylated histone at lysine 9, which is the inactivation marker of gene expression, decreased in SHR (Figure 4d) . These changes were markers of active chromatin and indicative of Nkcc1 gene activation. Therefore, the increased levels of mRNA expression correlated with increment of acetylation and dimethylation on H3K4 and decrement of dimethylation on H3K9 at the Nkcc1 promoter region in SHR.
To further validate our ChIP analysis results, we analyzed the expression of histone acetyltransferases (HATs), such as CREB binding protein, p300/CBP-associated factor, HAT1, and K (lysine) acetyltransferase 5 that they are involved in transcriptional activation. Our results showed increment of gene expression of these HATs in SHR compared with WKY (Figure 4e-h) . These results suggest that hypertension original contributions
upreg ulates HATs which catalyze acetylation on histone, but further functional studies need to be done to confirm the direct role of HATs in inducing chromatin remodeling.
diScuSSion
The present study demonstrates that expression of NKCC1 is epigenetically regulated during postnatal development of hypertension. Bisulfite sequencing revealed that the promoter region of Nkcc1 in WKY was getting methylated with age while that in SHRs remained hypomethylated during postnatal development of hypertension. In addition, the DNMT activity was higher in 18-week-old WKY than in age-matched SHR. DNMT3B and MeCP2 were highly associated with the promoter region of Nkcc1 original contributions
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in 18-week-old WKY while Cfp1 with that in age-matched SHR.
The promoter region of Nkcc1 was largely unmethylated in both WKY and SHR at 5 weeks of age. However, the promoter in normotensive WKY was getting methylated with age, but that in SHR remained hypomethylated after development of hypertension (Figure 3b,c) . SHR showed higher blood pressure than WKY by more than 40 mm Hg at any ages measured without difference in body weight (Supplementary Figure S1 online). These results suggest that both age and blood pressure affect CpG methylation in the promoter region of Nkcc1, and that hypertension suppress CpG methylation in the promoter. Methylation on promoter region of Nkcc1 in WKY is responsible for downregulation of NKCC1 expression (Figure 2) . Methylation on Nkcc1 promoter reduces its transcription in cerebral cortex 17 as well as cardiovascular system such as aorta original contributions
and heart in normotensive rat. 13 Treatment with 5-aza-cytidine, an inhibitor of DNMT, or trichostatin A, a histone deacetylase inhibitor, upregulated its transcription in cerebral cortex during postnatal maturation. Modifications of methylation in genes of the renin-angiotensin system play a role in the fetal programming of hypertension. 18 The fact that DNMT inhibition by 5-aza-cytidine induces an increase (~25 mm Hg) in blood pressure 19 suggests that the status of DNA methylation affects the expression of genes which regulate blood pressure. Therefore, we determined the activity of DNMTs in WKY and SHR with age. The activity of DNMTs after development of hypertension was about threefold higher in WKY than SHR (Figure 3d) . These data are in accordance with the methylation status on the Nkcc1 promoter of WKY. On the other hand, maintenance of hypomethylation in Nkcc1 promoter of SHR resulting from low DNMT activity plays an important role in upregulation of NKCC1 after development of spontaneous hypertension ( Figure 5 ). DNMT3B which is de novo DNMT and MeCP2 which binds to methylated cytosines were highly associated with the promoter of WKY with age (Figure 3e-g ), resulting in hypermethylation on the Nkcc1 promoter region and gene suppression in WKY (Figure 3b,c) . In addition, we found that Cfp1 20 is associated with Nkcc1 promoter in SHR rather than that of WKY (Figure 3h) . The promoter of SHR showed not only increased histone acetylation which is an active marker of transcription but also decreased dimethylated H3K9 which is an inactive marker of transcription (Figure 4b-d) . The modifications further induce upregulation of NKCC1 in SHR. Epigenetic modifications are defined as heritable alterations in gene expression patterns without change in the DNA sequences. 21 Among the epigenetic modifications, the DNA methylation occurs on cytosines at CpG dinucleotides by DNMTs (DNMT1, DNMT3a, and DNMT3b) and is associated with gene silencing. DNMT1 is involved in the maintenance of methylation, whereas DNMT3a and DNMT3b are the main enzymes for de novo methylation. Abnormal DNA methylation patterns are observed in human diseases such as cancers, 22, 23 autoimmune disease, 24 and cardiovascular diseases including hypertension. 18, 25 A family of methyl-CpG-binding proteins has been described that can specifically recognize the mammalian methylation marks. These include four proteins containing a homologous methyl-CpG-binding domain (MBD1, MBD2, MBD4, and the founding member MeCP2) 26 and a recently characterized, nonhomologous protein, Kaiso, 27, 28 which is capable of binding a methylated CpG dinucleotides doublet. On the other hand, Cfp1 specifically associates with unmethylated CpG and recruits H3K4 methyltransferase Setd1 which results in activation of gene transcription. 20 In the bicarbonate-free medium, the elevation of bumetanide concentration from 10 to 100 μmol/l sharply suppressed contraction of endothelium-denuded rat aorta 2,29 and mice mesenteric arteries 30 evoked by phenylephrine. These data are consistent with our results obtained with rat mesenteric arteries incubated with a nitric oxide synthase inhibitor, N G -nitro-L-arginine methyl ester. We demonstrated that pretreatment of bumetanide attenuated the E max during phenylephrineinduced vasoconstriction in mesenteric artery of 10-and 18-week-old SHR more than in those of WKY (Figure 1 and Table 1 ). These data indicate that the vascular tissues in SHR are more sensitive to bumetanide than are those in WKY, In normotensive arteries, the cpG island in NKcc1 promoter is methylated by dNA methyltransferase and histone is modified to suppressive code (H3K9 methylation) with age. In hypertensive arteries, the cpG island remains hypomethylated and histone is modified to activating code (H3 acetylation). Please note open state of acetylated H3 which allows easy access of transcriptional machineries. Increased concentration of intracellular cl − in hypertensive arteries, upon opening of cl − channels, induces increased eflux of cl − resulting in membrane depolarization which increases ca 2+ influx through voltage-dependent ca 2+ channels. Please note that hypertensive arteries with increased NKcc1 activity are greatly inhibited by bumetanide, an inhibitor of NKcc1. dNmT, dNA methyltransferase; E m , membrane potential; NKcc1, Na + -K + -2cl − cotransporter 1.
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supporting that the vascular tissues in SHR have higher expression level of NKCC1 than do those in WKY. NKCC1 may be considered as a potential pharmacological target in management of hypertension because the decreased baseline activity of NKCC1 or its suppression by chronic treatment with high-ceiling diuretics may lead to inhibition of myogenic tone and progression of end-stage renal disease. 31, 32 Importantly, some antihypertensive drugs exhibit side effects in patients with other disease such as asthma, for example, bronchoconstriction when treated with β-blockers. 32 This is not the case with NKCC1 inhibitors, which elicits airway smooth muscle relaxation. 33 In summary, the findings of the present study support the hypothesis that expression of NKCC1 is epigenetically regulated during postnatal development of hypertension, providing novel insight into the transcriptional regulation of NKCC1 in hypertension.
Supplementary material is linked to the online version of the paper at http:// www.nature.com/ajh
